Russ Conroy

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.

Treatment with NT-I7 may boost the immune system and enhance antitumor activity in patients with pancreatic cancer and other solid tumors.

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.

Adding bevacizumab to atezolizumab plus carboplatin and pemetrexed appears to be tolerable among patients with metastatic nonsquamous non–small cell lung cancer.

Findings from the phase 1/2 LINKER-MM1 trial support the marketing authorization application for linvoseltamab in the management of relapsed/refractory multiple myeloma.

Most patients with acute myeloid leukemia appear to remain on treatment with ziftomenib plus standard-of-care therapy in the phase 1 KOMET-007 trial.

Data from the phase 2 SPEARHEAD-1 trial support the biologics license application for afami-cel as a treatment for patients with advanced synovial sarcoma.

Clinical practice guideline amendments detail novel urinary biomarkers and agents that may improve Bacillus Calmette-Guerin efficacy in the management of non-muscle invasive bladder cancer.

FDA initiatives such as the Food and Drug Omnibus Reform Act will set goals and specify measures for improving representation in pediatric cancer clinical studies.

Findings from the phase 3 PERSEUS trial support the supplemental New Drug Application for the daratumumab and hyaluronidase-fihj combination in transplant-eligible newly diagnosed multiple myeloma.

Patients with multiple myeloma appear to feel confident in being able to report adverse effects associated with bortezomib independently via digital tools.

Data from the phase 3 INSPIRE trial may support iruplinalkib as a new treatment option for those with advanced ALK-positive non–small cell lung cancer.

Japan’s Ministry of Health, Labour, and Welfare also accepted a supplemental new drug application for lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.

Adding daratumumab to VRd induction and consolidation therapy plus lenalidomide maintenance provides a benefit with respect to MRD-negative status among patients with multiple myeloma.

At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.

Data from the phase 2 DESTINY-PanTumor02 trial support the supplemental biologics license application for trastuzumab deruxtecan as a treatment for those with metastatic HER2-positive solid tumors.

Results from the randomized LASRE trial support the use of laparoscopic-assisted surgery for patients with low rectal cancer.

Findings support cabozantinib plus atezolizumab as a potential new treatment option for those with metastatic castration-resistant prostate cancer that has progressed on a novel hormonal therapy.

Liver contrast-enhanced MRI resulted in a change in the local treatment plan for approximately a third of patients with colorectal liver metastases in the CAMINO study.

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.

Expanding or updating coverage with Medicaid may lead to positive health outcomes among patients with non–small cell lung cancer following surgery, according to Leticia Nogueira, PhD, MPH.

The FDA sets a Prescription Drug User Fee Action Date of November 16, 2024 for obe-cel as a treatment for those with relapsed/refractory B-cell acute lymphoblastic leukemia.

PTX-252 incorporates a novel molecular entity designed to enhance how cancer cells respond to chemotherapy.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

Findings from the phase 1b/3 IMscin001 study support the European Commission’s approval of subcutaneous atezolizumab as a treatment for lung cancer and other disease types.

Findings from the phase 3 FRESCO-2 trial support fruquintinib’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

Investigators are assessing avutometinib in combination with sotorasib as a treatment for those with KRAS G12C–mutated non–small cell lung cancer in the phase 1/2 RAMP-203 study.

Findings from a phase 1a/1b trial highlight that treatment with NX-5948 appears to be tolerable among patients with relapsed/refractory B-cell malignancies.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

Certain patients with salivary gland carcinoma and close surgical margins may safely be considered for observation, according to findings from a retrospective cohort study.